Allurion Technologies (ALUR) Liabilities and Shareholders Equity (2022 - 2026)
Allurion Technologies (ALUR) posted Liabilities and Shareholders Equity of $14.0 million for Q1 2026, down 11.27% on a QoQ basis from $15.8 million in Q4 2025, and down 63.57% year-over-year from $38.4 million in Q1 2025.
Allurion Technologies (ALUR) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Allurion Technologies' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $14.0 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 63.57% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.1 million (down 54.84% YoY) and the FY2025 annual result came in at $15.8 million, down 51.93% from the prior year.
- Liabilities and Shareholders Equity was $14.0 million for Q1 2026 at Allurion Technologies, down from $15.8 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $120.7 million in Q3 2023 and bottomed at $14.0 million in Q1 2026.
- A 5-year average of $46.2 million and a median of $46.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 39.6% — and 2025, when it slumped 64.22%.
- Allurion Technologies' Liabilities and Shareholders Equity stood at $51.4 million in 2022, then soared by 39.6% to $71.7 million in 2023, then sank by 54.24% to $32.8 million in 2024, then plunged by 51.93% to $15.8 million in 2025, then declined by 11.27% to $14.0 million in 2026.
- Business Quant data shows ALUR's Liabilities and Shareholders Equity at $14.0 million in Q1 2026, $15.8 million in Q4 2025, and $18.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 6.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 31.92 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 10.46 Bn |
| 10 | Allurion Technologies | 74.67 Mn | 69.62 Mn | 1.23 Mn | 14.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.00 Mn |
| Dec 31, 2025 | 15.77 Mn |
| Sep 30, 2025 | 18.14 Mn |
| Jun 30, 2025 | 28.17 Mn |
| Mar 31, 2025 | 38.41 Mn |
| Dec 31, 2024 | 32.81 Mn |
| Sep 30, 2024 | 50.70 Mn |
| Jun 30, 2024 | 46.55 Mn |
| Mar 31, 2024 | 59.99 Mn |
| Dec 31, 2023 | 71.71 Mn |
| Sep 30, 2023 | 120.69 Mn |
| Jun 30, 2023 | 52.15 Mn |
| Dec 31, 2022 | 51.37 Mn |